Melanoma News and Research

Latest Melanoma News and Research

ISC-4 topical compound may prevent skin cancer lesion formation

While incidents of melanoma continue to increase despite the use of sunscreen and skin screenings, a topical compound called ISC-4 may prevent melanoma lesion formation, according to Penn State College of Medicine researchers.

27 Apr 2011

FDA grants orphan drug status to Provectus' PV-10 for liver cancer treatment

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, has received orphan drug designation by the U.S. Food and Drug Administration for Rose Bengal, the active ingredient in its novel oncology drug PV-10, for the treatment of hepatocellular carcinoma, the most common form of primary liver cancer.

27 Apr 2011

Nanotechnology in sunscreens is safe, says Nanodermatology Society

The Nanodermatology Society (NDS), a physician-led organization dedicated to the scientific and medical aspects of nanotechnology and dermatology, released its first position statement on the safety of nanotechnology in sunscreens.

22 Apr 2011

Jennerex and Green Cross report positive phase 2 JX-594 clinical trial for liver cancer

Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic products for cancer, and Green Cross Corporation, a leading company in the development, manufacturing, and commercialization of viral vaccines and other biological products, today reported positive clinical data from a Phase 2 trial evaluating JX-594 for liver cancer which was conducted in South Korea.

21 Apr 2011

Aduro raises $19.25 million through Series B equity financing

Aduro BioTech, a clinical-stage immunotherapy company, announced today that it has completed its Series B equity financing from a combination of current investors and Morningside Ventures, bringing the total capital secured in this round to $19.25 million. In addition, Ms. Stephanie O'Brien, who represents Morningside, has joined Aduro's Board of Directors.

20 Apr 2011

Ludwig Institute demonstrates ability of DAVANAT to enhance efficacy of T-lymphocytes to kill tumor cells

Pro-Pharmaceuticals, Inc. today announced that the Brussels Branch of the Ludwig Institute for Cancer Research demonstrated the ability of GM-CT-01 (DAVANAT®) to enhance the ability of tumor-specific T-lymphocytes to kill tumor cells.

20 Apr 2011

Squamous cell cancers can originate from hair follicle stem cells, finds study

Squamous cell cancers, which can occur in multiple organs in the body, can originate from hair follicle stem cells, a finding that could result in new strategies to treat and potentially prevent the disease, according to a study by researchers with UCLA's Jonsson Comprehensive Cancer Center and the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA.

20 Apr 2011

BioSante, Aduro BioTech enter license agreement for GVAX cancer vaccines

Aduro BioTech, a clinical-stage immunotherapy company, has licensed GVAX Pancreas Cancer Vaccine and GVAX Prostate Cancer Vaccine BioSante Pharmaceuticals, Inc. in exchange for milestone and royalty payments after commercialization.

19 Apr 2011

BioSante licenses Pancreas and Prostate cancer vaccines to Aduro BioTech

BioSante Pharmaceuticals, Inc. today announced it has licensed its Pancreas Cancer Vaccine and Prostate Cancer Vaccine to Aduro BioTech, a clinical-stage immunotherapy company, solely for use in combination with Aduro's proprietary vaccine platform based on Listeria monocytogenes (Lm).

19 Apr 2011

NIH researchers survey landscape of melanoma genome

A team led by researchers at the National Institutes of Health is the first to systematically survey the landscape of the melanoma genome, the DNA code of the deadliest form of skin cancer. The researchers have made surprising new discoveries using whole-exome sequencing, an approach that decodes the 1-2 percent of the genome that contains protein-coding genes.

16 Apr 2011

Plasma biomarkers can predict risk of metastasis in patients with melanoma

Scientists at Yale University have identified a set of plasma biomarkers that could reasonably predict the risk of metastasis among patients with melanoma, according to findings published in Clinical Cancer Research, a journal of the American Association for Cancer Research.

15 Apr 2011

Novelos Therapeutics acquires Cellectar

Novelos Therapeutics, Inc., a pharmaceutical company developing novel drugs for treatment and diagnosis of cancer, today announced that it has completed its acquisition of Cellectar, Inc., a Wisconsin-based drug development company, in a stock-for-stock transaction.

12 Apr 2011

Research on rare cancers

A cancer diagnosis can be a life-changing event. Many questions arise, with one of the first being, "Where should I be treated?" Patients diagnosed with rare cancers may have difficulty finding a physician knowledgeable in treating their type of cancer.

11 Apr 2011

Polaris' ADI-PEG 20 exhibits potential against AML, GBM and bladder cancer

Polaris Group announced today that data from preclinical studies suggest ADI-PEG 20, the Company's pegylated arginine deiminase therapeutic, may be effective in treating acute myeloid leukemia (AML), glioblastoma multiforme (GBM) and bladder cancer.

8 Apr 2011

Protecting skin from sun's ultraviolet radiation is best way to avoid potential skin problems

Summertime means plenty of fun in the sun for many. "I would burn on Saturday and Sunday, peel by Wednesday and be back on the water by the next Saturday doing the same thing," says Thomas Randall, a man in his 70s who spent much of his youth at a lake or a beach trying to tan a pale complexion. But countless hours of sun exposure have taken a toll on his skin, and he now needs regular examinations to search for pre-cancerous moles.

7 Apr 2011

Parkinson's disease linked to increased risk of prostate cancer

University of Utah School of Medicine researchers have found compelling evidence that Parkinson's disease is associated with an increased risk of prostate cancer and melanoma, and that this increased cancer risk also extends to close and distant relatives of individuals with Parkinson's disease.

7 Apr 2011

Combination of molecularly targeted cancer drug and anti-malarial drug stops tumor growth

Researchers at the University of Pennsylvania School of Medicine may have found a way to turn an adaptive cellular response into a liability for cancer cells. When normal cells are starved for food, they chew up existing proteins and membranes to stay alive. Cancer cells have corrupted that process, called autophagy, using it to survive when they run out of nutrients and to evade death after damage from chemotherapy and other sources.

6 Apr 2011

More than 900 young Britons diagnosed with the deadliest form of skin cancer each year

Each day more than two people under 35 in Britain are diagnosed with malignant melanoma - the deadliest form of skin cancer - according to new figures from Cancer Research UK.

6 Apr 2011

Zebrafish research suggests new drug targets and markers to help treat melanoma

Thanks to the zebrafish, there is new hope for people with melanoma, an aggressive skin cancer that is responsible for approximately 8,700 deaths each year in the United States.

5 Apr 2011

Jennerex, Transgene present JX-594 Phase 1 and 2 study data in liver cancer at EASL meeting

Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic products for cancer, and Transgene,a bio-pharmaceutical company specialized in the development of immunotherapeutic products, today announced that new data from Phase 1 and 2 clinical studies of JX-594 were presented in an oral presentation at the 46th Annual Meeting of the European Association for the Study of the Liver over the weekend at the Internationales Congress Centrum in Berlin, Germany.

5 Apr 2011